drugset / Trial / NCT00576589
Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones
RandomizedCrossoverDouble-blindTreatment
Summary
The study is designed to assess whether repeated dosing with CE-326,597 will cause patients with asymptomatic gallstones (as detected on screening abdominal ultrasound) to become symptomatic. In addition, the study will characterize the pharmacokinetics of CE-326,597.
Timeline
- Start
- 2008-01
- Primary completion
- —
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CE-326,597 | Small molecule | 25 mg | Oral |
| Subject | CE-326,597 | Small molecule | 100 mg | Oral |